Both L-DOPA and HFS-STN restore the enhanced group II spinal reflex excitation to a normal level in patients with Parkinson's disease

Clin Neurophysiol. 2011 May;122(5):1019-26. doi: 10.1016/j.clinph.2010.08.015. Epub 2010 Oct 12.

Abstract

Objective: To investigate the contribution of group II spinal pathways in Parkinsonian upper limb rigidity and the modulation of spinal excitability of group I and group II pathways by L-DOPA and subthalamic nucleus-high-frequency stimulation (STN-HFS).

Methods: The effect of ulnar nerve electrical stimulation on Flexor Carpi Radialis Electromyogram (FCR EMG) was investigated in two groups of patients: patients receiving medication (MED group) and chronically surgically implanted patients (DBS group). Results were compared in patients ON and OFF treatment, and between patients and control subjects.

Results: The resulting long-lasting facilitation in FCR EMG had similar characteristics in all groups, and surface area was assessed in analysis windows corresponding to the parts supposed to be mediated by non-monosynaptic spinal pathways to FCR motoneurones, fed by hand muscle group I and group II afferents (Lourenço et al., 2006). In both the MED and DBS groups, the group I excitation was not altered but the group II excitation was particularly enhanced when OFF treatment, compared to controls, and both L-DOPA and STN-HFS restored the group II spinal excitation to normal level.

Conclusion: Both L-DOPA and STN-HFS influence the metabolism of monoamines in the midbrain, and restore the descending neuromodulation on group II spinal reflex.

Significance: These results further support a group II contribution to the enhanced long latency response (LLR) to muscle stretch observed in wrist muscles of rigid Parkinson's disease (PD) patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Analysis of Variance
  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use*
  • Deep Brain Stimulation
  • Electromyography
  • Female
  • Humans
  • Levodopa / pharmacology
  • Levodopa / therapeutic use*
  • Male
  • Middle Aged
  • Muscle Rigidity / therapy
  • Parkinson Disease / physiopathology*
  • Parkinson Disease / therapy*
  • Reflex / drug effects
  • Reflex / physiology*

Substances

  • Antiparkinson Agents
  • Levodopa